Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Beam Therapeutics (BEAM) Non Operating Income (2020 - 2025)

Beam Therapeutics (BEAM) has disclosed Non Operating Income for 5 consecutive years, with $261.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 2603.11% to $261.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $303.7 million, a 681.43% increase, with the full-year FY2025 number at $303.7 million, up 681.43% from a year prior.
  • Non Operating Income was $261.7 million for Q4 2025 at Beam Therapeutics, up from $14.1 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $261.7 million in Q4 2025 to a low of -$17.3 million in Q2 2021.
  • A 5-year average of $24.4 million and a median of $10.0 million in 2022 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: soared 4322.08% in 2022, then crashed 78.11% in 2023.
  • Beam Therapeutics' Non Operating Income stood at -$1.2 million in 2021, then skyrocketed by 4322.08% to $51.6 million in 2022, then plummeted by 78.11% to $11.3 million in 2023, then fell by 14.35% to $9.7 million in 2024, then skyrocketed by 2603.11% to $261.7 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Non Operating Income are $261.7 million (Q4 2025), $14.1 million (Q3 2025), and $17.9 million (Q2 2025).